According to slide 30 of today's presentation, there are 10 near-term milestones remaining in the first half of 2015, one of which is Lympro's first pharmaceutical sales (Q1). That's the key milestone at this point, but progress on those other nine is still a good sign that things are moving in the right direction. MS Precise is slated to be commercialized in 2015 as well. That acquisition was ideal for the company's plans and makes the diagnostics division much more attractive. I think there will be interest in the diagnostics division once Lympro and MS Precise are CLIA certified. All I could think about today during the presentation was where this company could be in 5 years, 10 years, etc. Everyone has their own investment timeline, but you can't deny the long-term potential here is huge when shares are currently still available for under 8 cents.